Takeda says it has updated the United States prescribing information for ADZYNMA to add a boxed warning about neutralizing antibodies to ADAMTS13. The warning notes serious outcomes, including death, and the possibility that patients may lose response to recombinant or plasma-derived therapy. FDA had required the safety-label change after postmarketing reports, while Takeda says neutralizing antibodies were not observed in the pivotal trials and that the benefit-risk profile remains favorable. This is a labeling and monitoring event, not new evidence that every treated patient will develop antibodies or that the therapy no longer works. The commercial and clinical impact will depend on physician behavior, monitoring, patient outcomes, and any additional regulatory action. For TAK, watch updated prescribing practice, antibody testing, safety reports, treatment continuity, and whether future evidence changes the warning or product use.
TAKMarket price unavailable
Health & BiotechGraceHealth desk · approved prepared presenter